FoundationOne™ to be used in WIN Consortium Trial

Posted: Thursday, June 21, 2012

CAMBRIDGE, MASS., June 21, 2012

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced that Michael J. Pellini, M.D., president and chief executive officer, will present an overview of the company at the WIN2012 Symposium, taking place in Paris, France June 28th – 29th. The Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine is initiating a clinical trial that uses FoundationOne™, a genomic profile for cancer developed by Foundation Medicine. Details of the trial will be highlighted at the Symposium.

“FoundationOne will allow physicians participating in this trial to test for alterations in clinically-relevant genes known to be associated with human cancer and match these alterations with appropriate targeted therapies or clinical trials,” said Dr. John Mendelsohn, chairman of WIN Consortium. “WIN and Foundation Medicine are both dedicated to enabling the best treatment possible with the therapies most likely to be effective against an individual patient’s cancer. We believe this trial is an important step in that direction.”

Foundation Medicine and the clinical trial will be discussed on June 28th during Session 2 of the WIN2012 Symposium at the Palais des Congrès in Porte Maillot, Paris, France.